Abstract
Introduction: COVID-19 pandemic has led to a rise in hospitalized patients with viral pneumonia and we are still learning about the follow-up process.
Objective: To describe a cohort of hospitalized patients with COVID pneumonia and the clinical follow up once discharged.
Methods: Prospective cohort study. COVID pneumonia patients from August 2020 to January 2021 were analyzed (n=72), with a standardized clinical follow-up a month after discharge. We describe clinical features, extent of pneumonia and treatment provided. We define Extent Pneumonia as an affection of ≥ 4 of 6 radiographic zones and/or 3 of 5 lobes in chest CT and compare vs Non extent pneumonia. Lastly, we describe the findings on the clinical follow-up.
Results: Table 1: Cohort´s description. Table 2: Extent and Non extent pneumonia comparison. Clinical follow-up: 8(11.1%) patients persist symptomatic after discharge (4cough-3dyspnea-1anosmia).
| Age(yrs) | 59(46-72) |
| Male(%) | 37(51.4) |
| Chronic Lung Disease, total(%) Former/Actual Smoker COPD Asthma | 36(50) 24(33.3) 5(6.9) 2(2.8) |
| Hypertension(%) | 26(36.1) |
| Diabetes(%) | 13(18.1) |
| Immunosuppresion(%) | 11(15.3) |
| Fever Cough Dyspnea | 56(77.8) 42(58.3) 40(55.6) |
| O2 required(%) | 48(66.7) |
| COVID treatment(%) Convalescent plasma + Steroids Steroids | 51(70.8) 37(51.4) 14(19.4) |
| Non-Extent pneumonia | Extent pneumonia | p value | |
| Immunosuppression(%) | 0(0) | 11(20.4) | 0.037 |
| Fever(%) | 9(12.5) | 47(65.3) | 0.001 |
| Dyspnea(%) | 6(8.3) | 34(47.2) | 0.028 |
| O2 required(%) | 7(9.7) | 41(56.9) | 0.004 |
| Symptom persistence | 2(2.8) | 6(8.33) | 0.001 |
Conclusions: We present a thorough description of clinical data and our findings define the features associated with extent pneumonia. The clinical follow-up showed a relatively low frequency of symptom persistence.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3650.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
